The case of an 18-year-old girl Genoa affected by a thrombosis 15 days after vaccination with AstraZeneca has rekindled the headlights on the safety of the Anglo-Swedish drug for young women. It so happened that in the same hours a 42-year-old from Pisa, also vaccinated with AstraZeneca, suffered a stroke. These are two different cases and it must be said right away that no correlation with the vaccine is proven for both women. Not surprisingly the Liguria Region has already announced that, while following the evolution of the 18-year-old’s disease with all the attention, it will not change the schedule of the vaccination campaign which provides 20,000 administrations of AstraZeneca to the very young on an Open Day scheduled for the weekend. However, the news of the thrombosis case has cooled the race for the AstraZeneca vaccine. In Liguria there were 600 withdrawals from reservations for the Open Day even if in the same hours another hundred young Genoese signed up.
Vaccinations, the hour of adolescents. Pediatricians in the field: “Ready for this mission”
It should be reiterated that so far in all of Europe the cases of thrombosis occurring in the three weeks following vaccination have been very rare, a few dozen. And that AstraZeneca continues to be administered in large quantities. So far 7,557,480 Italians (and about 90 million Europeans) have been protected with the Anglo-Swedish vaccine and another 1.4 million doses are available in the refrigerators of the Regions. Yesterday alone, 70,497 vaccinations with AstraZeneca were carried out throughout the national territory.
Furthermore, the accurate investigations of two Sicilian prosecutors taken three months ago after the death cases that occurred shortly after the administration of the vaccine did not show any correlation with the drug. In fact, the batches of AstraZeneca that had been seized as a precaution were all made available to local health authorities to be administered.
But why then had it been decided in recent weeks to use the AstraZeneca only for people over sixty?
As paradoxical as it may seem, in reality there was no decision to do so. On May 26, Aifa, the Italian agency that controls drugs, had recommended that the regions prefer the administration of AstraZeneca for the population over 60 years old. But the use of the verb “to recommend” suggests – in such a delicate matter – that Aifa itself has not even remotely considered the ban on administering AstraZeneca to citizens under the age of 60. According to insiders, this is a legal ploy that the medical authorities normally take to protect themselves from civil cases that have spread in an epidemic manner in the medical field. Not at home, the EMA, the European Medicines Agency, has not given any indication, limiting itself to using the unfortunate medical formula according to which the “benefits far outweigh the risks”
Even more paradoxically, a few weeks earlier Aifa itself had decided to administer AstraZeneca only to those under the age of 60 because the Anglo-Dutch company had presented the data of the trial only on patients over 60 when the vaccine was approved. . The results of the experimentation on the youngest were presented by AstraZeneca a few weeks after the first ones.
Last updated: 13:03 © REPRODUCTION RESERVED